Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
40.88
-0.74 (-1.78%)
Streaming Delayed Price
Updated: 2:57 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,274,952
Open
41.25
Bid (Size)
40.88 (34)
Ask (Size)
40.89 (18)
Prev. Close
41.62
Today's Range
40.88 - 41.26
52wk Range
33.67 - 45.92
Shares Outstanding
5,385,189,617
Dividend Yield
3.53%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
September 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+8.99%
+8.99%
1 Month
-1.73%
-1.73%
3 Month
+0.30%
+0.30%
6 Month
-3.52%
-3.52%
1 Year
+7.38%
+7.38%
More News
Read More
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
September 18, 2024
Via
Benzinga
Exposures
Product Safety
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
September 18, 2024
From
GSK plc
Via
Business Wire
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
September 16, 2024
Via
Investor's Business Daily
Topics
Death
Exposures
Death
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
September 13, 2024
Via
Investor's Business Daily
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
September 12, 2024
Via
Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
Via
Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
Via
Benzinga
Exposures
Product Safety
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
September 06, 2024
Via
Benzinga
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
August 16, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 15, 2024
Via
Benzinga
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
August 13, 2024
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
August 12, 2024
Via
Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Via
Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
August 02, 2024
Via
Benzinga
Exposures
COVID-19
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 01, 2024
From
GSK plc
Via
Business Wire
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
July 31, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
July 31, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.